Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
AstraZeneca’s experimental pill camizestrant significantly reduced the risk of disease progression or death in hormone receptor-positive, HER2-negative breast cancer, according to new data presented at the American Society of Clinical Oncology (ASCO) meeting. In the trial, patients switched to camizestrant after early signs of resistance detected through a blood-based liquid biopsy showed a 56% improvement in progression-free survival compared to standard therapy.
This marks the first time liquid biopsy has been used to guide treatment decisions before visible tumor growth. Dr. Eleonora Teplinsky of Valley-Mount Sinai said the early switch approach allows oncologists to “stay ahead of the curve,” potentially changing how breast cancer is treated.
The phase 3 study enrolled 3,256 women with advanced HR-positive, HER2-negative breast cancer. After at least six months of aromatase inhibitors and CDK4/6 inhibitors—like Kisqali (Novartis), Ibrance (Pfizer), or Verzenio (Eli Lilly)—315 patients with ESR1 mutations were identified and randomized. Patients receiving camizestrant plus a CDK4/6 inhibitor saw a median of 16 months without disease progression, versus 9.2 months on standard therapy with placebo.
No new safety issues were reported, and dropout rates remained low. Camizestrant is a selective estrogen receptor degrader (SERD), designed to block estrogen signaling in cancer cells—an alternative when standard hormone therapies lose effectiveness.
In a separate trial, AstraZeneca’s immunotherapy Imfinzi (durvalumab), combined with FLOT chemotherapy, reduced the risk of disease recurrence or death by 29% in early-stage gastric and esophageal cancer patients. The findings support earlier intervention with immunotherapy and are expected to influence global treatment practices.
AstraZeneca CEO Pascal Soriot emphasized the importance of proactive monitoring, calling it the future of cancer care. Both studies were simultaneously published in the New England Journal of Medicine.
